Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by farmerjaneon Jul 29, 2020 11:07pm
126 Views
Post# 31341445

RE:RE:RE:RE:RE:Next PP possibly in September...

RE:RE:RE:RE:RE:Next PP possibly in September...Not sure if best in class is meaningless, they have been showing that slide for quite a few years. Page 19 of corporate update. Will agree absolutely no results over the last few years. Obtained RedSky partners two years ago this September to forge partnerships with what results? Corporate updates last fall 3-12 months to forge partnerships. Many examples of presentations and words that have not gone anywhere. At some point you have ask to they have science or this a pyramid scheme? Vaccine development really, we can all see where the real players are everyday in the news. This company was involved years ago with Prevent out of Saskatchewan in developing vaccines what became of that nothing. What changed in the corporate update today from an update two weeks ago?
Bullboard Posts